Eli Lilly and Company $LLY Shares Acquired by Meeder Asset Management Inc.

Meeder Asset Management Inc. boosted its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 6.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,647 shares of the company’s stock after purchasing an additional 1,725 shares during the quarter. Eli Lilly and Company accounts for approximately 1.8% of Meeder Asset Management Inc.’s holdings, making the stock its 12th biggest position. Meeder Asset Management Inc.’s holdings in Eli Lilly and Company were worth $35,461,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Torren Management LLC increased its holdings in shares of Eli Lilly and Company by 357.1% during the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after purchasing an additional 25 shares during the period. Foresight Capital Management Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the third quarter valued at about $49,000. Caitlin John LLC bought a new stake in shares of Eli Lilly and Company in the second quarter valued at about $64,000. IMG Wealth Management Inc. grew its position in Eli Lilly and Company by 500.0% during the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock worth $72,000 after buying an additional 50 shares in the last quarter. Finally, John Boyer Inc. acquired a new stake in Eli Lilly and Company during the third quarter worth about $72,000. 82.53% of the stock is owned by institutional investors.

Recent Eli Lilly and Company Headlines

Here are a few of the latest headlines about LLY:

  • Positive Sentiment: Royal Bank of Canada maintained an Outperform rating and a $1,600 price target, while a new Seeking Alpha analysis initiated coverage with a Buy rating. The favorable recommendations reinforce the bullish view on Lilly’s growth prospects. RBC Outperform rating Seeking Alpha Buy initiation
  • Positive Sentiment: Lilly agreed to acquire Calytrix Bio in a deal worth up to $1.5 billion, adding to its reported $32 billion acquisition push in 2026 to build cancer and immunology capabilities. This could diversify future growth, though much depends on development success. Lilly buying spree surpasses $32 billion
  • Neutral Sentiment: Lilly posted updates to several early-stage obesity and inflammation studies. These keep investors’ attention on its pipeline, but Phase 1 progress alone does not establish safety or efficacy. Early obesity drug study update

Insider Activity

In other news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of several research reports. The Goldman Sachs Group restated a “buy” rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Royal Bank Of Canada reissued an “outperform” rating and set a $1,600.00 price objective on shares of Eli Lilly and Company in a report on Tuesday. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Sanford C. Bernstein restated an “outperform” rating and set a $1,450.00 price objective on shares of Eli Lilly and Company in a research report on Monday, October 26th. Finally, China Merchants Securities lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,422.00.

Read Our Latest Stock Report on LLY

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,380.92 on Thursday. The firm has a market cap of $1.30 trillion, a P/E ratio of 44.82, a price-to-earnings-growth ratio of 1.69 and a beta of 0.40. The firm’s 50-day simple moving average is $1,258.86 and its 200-day simple moving average is $1,115.99. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,475.25. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $7.02 earnings per share. As a group, research analysts expect that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is currently 22.46%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.